FDMT · XBRL financial data

4D Molecular Therapeutics financial statements, every fiscal year

The same tables from 7 filings, lined up. Matched by XBRL tag: renamed lines keep their history.

How these numbers work

Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
* marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
0 means a filing states zero; a dash (—) means no filing states that number.
“year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
Shares outstanding come from each filing's cover page, as of the date printed there.
Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.

Income statement

Fiscal years (FDMT's year ends in late December)

In thousands of dollars	FY 2020Dec 31, 2020	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Revenue	13,612	18,038	3,129	20,723	37	85,209
Revenue from contracts with customers	13,363	18,038	3,129	20,723	37	85,209
General and administrative	17,238	28,011	32,908	36,494	46,579	49,060
Total operating expenses	70,276	89,371	113,161	133,590	187,878	244,756
Operating income (loss)	(56,664)	(71,333)	(110,032)	(112,867)	(187,841)	(159,547)
Interest income	152	137	2,573	12,211	27,050	19,475
Other income (expense)	(181)	(121)	(35)	(181)	(77)	(37)
Income tax expense (benefit)	0	0	0	0	0	0
Net income (loss)	(56,693)	(71,317)	(107,494)	(100,837)	(160,868)	(140,109)
Earnings per share, basic USD per share	—	(2.57)	(3.32)	(2.58)	(2.98)	(2.42)
Earnings per share, diluted USD per share	—	(2.57)	(3.32)	(2.58)	(2.98)	(2.42)
Weighted average shares, basic thousands of shares	—	27,730	32,351	39,130	53,944	57,930
Weighted average shares, diluted thousands of shares	—	27,730	32,351	39,130	53,944	57,930

Fiscal years (FDMT's year ends in late December)

In thousands of dollars	FY 2020Dec 31, 2020	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Cash and cash equivalents	276,726	153,001	52,351	249,108	149,336	60,241
Marketable securities	0	94,776	161,203	39,124	275,541	342,414
Marketable securities, non-current	0	67,652	4,908	10,954	80,583	111,379
Accounts receivable	1,486	47	0	—	—	—
Prepaid and other current assets	4,444	8,456	6,957	8,356	10,055	10,479
Total current assets	282,656	256,280	220,511	296,588	434,932	413,134
Property and equipment, net	5,073	14,391	22,262	20,126	19,534	14,867
Right-of-use asset	0	14,562	13,085	11,539	21,074	18,143
Total assets	288,331	353,487	261,846	339,891	560,384	566,711
Accounts payable	1,787	4,764	3,322	3,515	4,386	11,159
Accrued liabilities	8,371	7,744	8,870	12,014	18,869	26,874
Total current liabilities	16,744	16,338	15,731	18,951	29,149	43,985
Long-term debt	—	—	—	—	—	0
Lease liability, non-current	0	15,217	13,469	11,522	18,969	15,821
Total liabilities	31,944	34,380	30,509	32,062	49,778	61,047
Accumulated deficit	(135,679)	(206,996)	(314,490)	(415,327)	(576,195)	(716,304)
Total stockholders' equity	256,387	319,107	231,337	307,829	510,606	505,664
Total liabilities and equity	288,331	353,487	261,846	339,891	560,384	566,711
Common shares outstanding (cover page) thousands of shares	26,693	32,237	33,234	49,778	45,794	57,608

Fiscal years (FDMT's year ends in late December)

In thousands of dollars	FY 2020Dec 31, 2020	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Net income (loss)	(56,693)	(71,317)	(107,494)	(100,837)	(160,868)	(140,109)
Stock-based compensation	4,984	13,799	17,121	19,665	26,116	22,016
Net cash from operating activities	(50,909)	(69,134)	(86,685)	(75,792)	(134,585)	(109,082)
Purchases of property and equipment	1,000	9,110	11,536	2,771	3,786	536
Net cash from investing activities	(1,000)	(172,680)	(17,050)	115,717	(302,437)	(92,973)
Proceeds from issuing common stock	205,658	114,296	0	—	—	—
Net cash from financing activities	278,983	118,089	3,085	156,832	337,250	112,960
Net change in cash	227,074	(123,725)	(100,650)	196,757	(99,772)	(89,095)

SIC 2836 and related industry codes, similar size. Each row is the latest quarter reported.

How peers are chosen

SIC 2836 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
Runway shows only for companies burning cash with under $10B of public float.
* marks a quarter worked out from the filing totals: for a 10-Q, the year-to-date total less the earlier one.
A cell reading “not reported” means the filings give no figure for that quarter alone.

Company	Cash ($K)	Revenue, quarter ($K)	Operating cash flow, quarter ($K)	Shares outstanding	Runway	Quarter
4D Molecular Therapeutics	70,372	3,781	(69,999)*	55.2M	5.2 quarters	Q2 FY26 10-QJun 30, 2026
XOMA Royalty	85,600	12,318	6,121	12.5M	—	Q1 FY26 10-QMar 31, 2026
Lexicon Pharmaceuticals	40,924	692	(9,192)*	445.0M	20.7 quarters	Q2 FY26 10-QJun 30, 2026
Lineage Cell Therapeutics	37,355	1,069	(7,244)*	252.9M	7.0 quarters	Q2 FY26 10-QJun 30, 2026
Omeros	1,988	28,529	4,149*	72.4M	—	Q2 FY26 10-QJun 30, 2026
Forte Biosciences	49,629	not reported	(22,702)*	21.2M	8.7 quarters	Q2 FY26 10-QJun 30, 2026
Crescent Biopharma	171,593	0	(19,463)*	37.1M	8.8 quarters	Q2 FY26 10-QJun 30, 2026
Monopar Therapeutics	52,758	0*	(3,247)*	6.7M	32.4 quarters	Q2 FY26 10-QJun 30, 2026
Sangamo Therapeutics	27,586	1,442	(19,282)	414.3M	1.4 quarters	Q1 FY26 10-QMar 31, 2026

Not investment advice. Not affiliated with the U.S. SEC.